“We’ve demonstrated that we can successfully run trials for adolescents & young adults with sarcomas, and we're excited to have a growing portfolio of drugs and clinical trials for these diseases,” says @danafarber.bsky.social’s Dr. David Shulman. @dfciayasarcoma.bsky.social ➡️bit.ly/3RWIq3O
ICYMI: “I could not be more appreciative and more grateful to the incredible team at Dana-Farber,” Boston Firefighters IAFF Local 718 President Sam Dillon told @bostonglobe.com regarding @danafarber.bsky.social’s pledge to help fund @boston.gov’s firefighter cancer screening program. bit.ly/3Rv7DSI
In People magazine: From his hospital bed, Robbie Fox and Kelli Peters, both 27, said “I do” just 10 days before he succumbed to Ewing sarcoma. The couple got engaged in March 2025, after Fox went into remission following treatment at @danafarber.bsky.social. ➡️bit.ly/4uUTwoz
Two plenary studies and additional late-breaking research to be presented by @danafarber.bsky.social at #ASCO26. Be sure to check out these impactful oral presentations in Chicago.
▶️bit.ly/3RwURmD
Featured on @boston25news.com: Work has begun on @danafarber.bsky.social new 300-bed inpatient facility expected to open in 2031. It will be the region’s only hospital dedicated exclusively to adult cancer care.
▶️bit.ly/42X2QMf
Congratulations to @danafarber.bsky.social’s Ann Partridge, MD, MPH, who is the recipient of @gohealio.bsky.social’s 2026 Lifetime Disruptor Award in recognition of her outstanding and ongoing contributions to the field of breast cancer research and treatment.
ICYMI: Featured on @wbztv.bsky.social: @danafarber.bsky.social and @boston.gov announce funding to help preserve access to comprehensive early cancer screenings for Boston firefighters who are often exposed to carcinogens and toxic smoke in the line of duty. ➡️ bit.ly/4tTFCBL
The @americancancersoc.bsky.social updated guidelines, adding a blood test option, to increase #ColorectalCancer screenings. @danafarber.bsky.social’s Dr. Kimmie Ng told @nbcnews.com this highlights the significance of catching as many people as possible at risk for colorectal cancer. bit.ly/4tUSYNX
Dr. Paul Richardson of @danafarber.bsky.social presents results from SUCCESSOR-2 study showing the oral drug mezigdomide markedly improved PFS in patients w/relapsed or refractory multiple myeloma. Results support this novel therapy as a possible new standard of care for RRMM. #ASCO26 bit.ly/4wUzw6z
Vitamin D analog shuts down pancreatic cancer’s shield in clinical trial - new research from @danafarber.bsky.social’s and @salkinstitute.bsky.social published in @natcancer.nature.com. Read more: bit.ly/4fbfHlc
Dana-Farber News
Dana-Farber News
Dana-Farber News
Dana-Farber News
Dana-Farber News
Dana-Farber News
Dana-Farber News
Dana-Farber News
Dana-Farber News
Dana-Farber News
A small clinical trial led by Dana-Farber Cancer Institute researchers put a Salk Institute idea to the test in patients: that activating the vitamin D receptor can help reshape the protective environment surrounding pancreatic tumors in ways that could make the notoriously difficult-to-treat cancer more vulnerable to therapeutic treatments.
The partnership aims to make sure every Boston firefighter has access to early cancer screenings.
bit.ly
Published: June 8, 2026Sarcomas are cancers that occur in bone or soft tissue, such as muscles and fat. These cancers are rare and diverse, with more than 150 different variations. Treatment is advancing for some sarcomas, but most forms of the disease are still treated using chemotherapy, radiation and/or surgery. In some cases, there are few options if the cancer comes back. Dana-Farber physician-scientists are evaluating innovative ... Read more
